Drug intelligence / Profile preview

CLE-043

Development stage: Preclinical
Lead developer: Clexio Biosciences
Modality: Small Molecules

Overview

CLE-043 is a preclinical-stage small molecule drug candidate being developed by Clexio Biosciences for the treatment of epilepsy and Major Depressive Disorder (MDD). It acts as a positive allosteric modulator or opener of the KV7.2/3 (KCNQ2/3) potassium channels. By enhancing the activity of these channels, CLE-043 aims to stabilize neuronal excitability, providing both anticonvulsant and mood-stabilizing effects. The program has identified a lead compound and is currently undergoing preclinical development to evaluate its safety and efficacy profile for CNS indications.

Targets

KCNQ3 (Potassium voltage-gated channel subfamily Q member 3)KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)

Beyond the preview

Go deeper on CLE-043.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLE-043.

Explore the full profile